NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 0.4% and is now trading at $33.02.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.02. The biotechnology company earned $16.60 million during the quarter, compared to the consensus estimate of $22.23 million. Regenxbio had a negative net margin of 197.23% and a negative return on equity of 27.84%. The company's revenue was up 110.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) earnings per share.
View Regenxbio's earnings history.

6 equities research analysts have issued twelve-month price targets for Regenxbio's shares. Their forecasts range from $37.00 to $100.00. On average, they anticipate Regenxbio's share price to reach $60.00 in the next year. This suggests a possible upside of 81.7% from the stock's current price.
View analysts' price targets for Regenxbio.

News headlines about RGNX stock have been trending very positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regenxbio earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Immunovant (IMVT) and SpringWorks Therapeutics (SWTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio's stock is owned by many different institutional and retail investors. Top institutional investors include Botty Investors LLC (0.81%), UBS Group AG (0.81%), Principal Financial Group Inc. (0.67%), Swiss National Bank (0.19%), P.A.W. Capital Corp (0.19%) and New York State Teachers Retirement System (0.13%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista.
View institutional ownership trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, WINTON GROUP Ltd, Assenagon Asset Management S.A., Hancock Whitney Corp, Texas Permanent School Fund, Arizona State Retirement System, and Liberty One Investment Management LLC. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, and Vittal Vasista.
View insider buying and selling activity for Regenxbio.

RGNX stock was purchased by a variety of institutional investors in the last quarter, including Rafferty Asset Management LLC, P.A.W. Capital Corp, Essex Investment Management Co. LLC, Mackay Shields LLC, New York State Teachers Retirement System, Principal Financial Group Inc., Swiss National Bank, and ProShare Advisors LLC.
View insider buying and selling activity for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $33.02.

Regenxbio has a market capitalization of $1.23 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]